14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
Explore related content and topics
Video
Salt Lake City Research Unit
Video highlighting Salt Lake City Resarch Unit, and its capabilities
Poster
Human Abuse Liability Studies: Not Your Traditional Phase I Study
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’…
White Paper
Favorable Regulatory Procedures In The Netherlands Phase I-IIa
The EU Clinical Trials Directive (CTD) has been fully implemented in The Netherlands. Prior to beginning a clinical trial, an identical Clinical…